MAPK34 Antibody (N-term) Blocking Peptide
€363.00
In stock
SKU
AC-BP1917a
Background:
The central core of each mitogen-activated protein kinase (MAPK) pathway is a conserved cascade of 3 protein kinases: an activated MAPK kinase kinase (MAPKKK) phosphorylates and activates a specific MAPK kinase (MAPKK), which then activates a specific MAPK. While the ERK MAPKs are activated by mitogenic stimulation, the CSBP2 and JNK MAPKs are activated by environmental stresses such as osmotic shock, UV irradiation, wound stress, and inflammatory factors. MAPK34 is a MAPKKK, and contains a protein kinase catalytic domain at the C terminus. The N-terminal nonkinase domain may contain a regulatory domain. Expression of MAPK34 in mammalian cells activates the CSBP2 and JNK MAPK pathways, but not the ERK pathway. In vitro kinase studies indicate that recombinant MAPK34 can specifically phosphorylate and activate PRKMK6 and SERK1, MAPKKs that activate CSBP2 and JNK, respectively but cannot phosphorylate PRKMK1, an MAPKK that activates ERKs. MAPK34 is a major mediator of environmental stresses that activate the CSBP2 MAPK pathway, and a minor mediator of the JNK pathway.
Other Names:
Mitogen-activated protein kinase kinase kinase 4, MAP three kinase 1, MAPK/ERK kinase kinase 4, MEK kinase 4, MEKK 4, MAP3K4, KIAA0213, MAPKKK4, MEKK4, MTK1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1917a was selected from the N-term region of human MAPK34. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: MAP3K4
Gene ID: 4216
Primary Accession: Q9Y6R4
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
The central core of each mitogen-activated protein kinase (MAPK) pathway is a conserved cascade of 3 protein kinases: an activated MAPK kinase kinase (MAPKKK) phosphorylates and activates a specific MAPK kinase (MAPKK), which then activates a specific MAPK. While the ERK MAPKs are activated by mitogenic stimulation, the CSBP2 and JNK MAPKs are activated by environmental stresses such as osmotic shock, UV irradiation, wound stress, and inflammatory factors. MAPK34 is a MAPKKK, and contains a protein kinase catalytic domain at the C terminus. The N-terminal nonkinase domain may contain a regulatory domain. Expression of MAPK34 in mammalian cells activates the CSBP2 and JNK MAPK pathways, but not the ERK pathway. In vitro kinase studies indicate that recombinant MAPK34 can specifically phosphorylate and activate PRKMK6 and SERK1, MAPKKs that activate CSBP2 and JNK, respectively but cannot phosphorylate PRKMK1, an MAPKK that activates ERKs. MAPK34 is a major mediator of environmental stresses that activate the CSBP2 MAPK pathway, and a minor mediator of the JNK pathway.
Other Names:
Mitogen-activated protein kinase kinase kinase 4, MAP three kinase 1, MAPK/ERK kinase kinase 4, MEK kinase 4, MEKK 4, MAP3K4, KIAA0213, MAPKKK4, MEKK4, MTK1
Target/Specificity:
The synthetic peptide sequence used to generate the antibody AP1917a was selected from the N-term region of human MAPK34. A 10 to 100 fold molar excess to antibody is recommended. Precise conditions should be optimized for a particular assay.
Gene Name: MAP3K4
Gene ID: 4216
Primary Accession: Q9Y6R4
Format: Peptides are lyophilized in a solid powder format. Peptides can be reconstituted in solution using the appropriate buffer as needed.
| Is Featured? | No |
|---|
Write Your Own Review